Long-Term Psoriasis Treatment Results Show Sustained Relief
Adults with plaque psoriasis who clear their skin early in treatment may see those benefits last through three years.
Updated on Oct. 16, 2026 in Asthma
Live Poll
Should patients with moderate plaque psoriasis prioritize biologic treatments over oral medications for better results?
Three-year real-world data from the VALUE study indicate that patients with moderate to severe plaque psoriasis who achieved clear skin with risankizumab at one year were able to maintain those results through year three. These findings, which help clarify long-term outcomes for those considering systemic therapies, were presented at the 2026 EADV Congress in Vienna.
Why it matters
Managing plaque psoriasis, particularly high-impact lesions on the scalp, palms, or soles, often requires sustained systemic therapy. These results provide evidence that consistent skin clearance and improved quality of life can be maintained with risankizumab over the long term.
An interim analysis of the real-world VALUE study followed 2,639 patients with moderate to severe plaque psoriasis to compare treatment outcomes. Risankizumab showed a 56.6% PASI 100 rate versus 40.2% for other biologics, with 70.0% of users reporting high quality of life versus 52.9%.
The details
The study tracked patients undergoing systemic therapy, incorporating data from individuals with diverse comorbidities and concomitant medications. Risankizumab functions as a targeted treatment administered with maintenance dosing every 12 weeks. Researchers noted that the decision to initiate these therapies often involves a shared decision-making process between the patient and clinician to address high-impact lesions.
Timeline
The EADV Congress took place in Vienna from September 30 to October 3, 2026.
Health Landscape
The VALUE study is part of an ongoing effort to evaluate the comparative effectiveness of biologic treatments in real-world clinical practice. It reflects a broader shift toward monitoring long-term quality-of-life outcomes rather than just initial skin clearance in psoriasis care.
If you are managing moderate to severe plaque psoriasis, these long-term results are worth discussing with your dermatologist to see how they align with your treatment goals. Ask your doctor about the potential role of systemic therapies if you are struggling with lesions in high-impact areas.
The takeaway
Real-world data shows that consistent skin clearance for plaque psoriasis is achievable over three years with current biologic options. Track your symptoms and quality-of-life metrics to bring a clear picture of your progress to your next checkup.
Further reading
Learn more about the latest developments in systemic treatments at our Asthma section.
Source note: This article includes information reported by Hcplive.
Live Poll
Should patients with moderate plaque psoriasis prioritize biologic treatments over oral medications for better results?
